Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Nasal Swabs and Voice Dysfunction

Method of Measurement (Pre-analytical Tools)
Other bodily fluids
Biomarker Measured
Amyloid
Tau
Use
Diagnostic
Monitoring
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Determine if nasal swabs can provide an adequate sample for evaluation of neurodegenerative disorders (Alzheimer's Disease (AD), Parkinson's Disease with Dementia (PDD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementias (FTLD), Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP)) using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.

Target Population/ Population Being Studied

Patients with Parkinson's Disease and Voice Dysfunction, Patients with other neurodegenerative ( AD, MCI, or PSP) disorders and Voice Dysfunction, and People with Voice Dysfunction and no evidence of neurodegenerative disorders

Length of Current Trial
4 weeks
Number of Trial Participants

60

Estimated Trial Completion
August 2020
What is Required from Patients

minimally invasive nasal swab (may be able to do at home)

What is Required from the Health System

equipped lab, a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)

Sponsor

University of Arkansas

“Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders.” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT03299062?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=4&rank=37